vorinostat has been researched along with Lassitude in 8 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Only a minority of patients with high risk lymphoma will be cured with autologous transplant, so maintenance with vorinostat, an oral agent with activity in relapsed lymphoma, was studied starting day + 60 for 21 consecutive days followed by a week off for up to 11 cycles." | 9.20 | A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma. ( Andritsos, LA; Baiocchi, RA; Benson, DM; Bingman, A; Blum, K; Bowers, MA; Devine, SM; Earl, CT; Flynn, J; Geyer, S; Hade, EM; Hofmeister, CC; Humphries, K; Jaglowski, SM; Lozanski, G; Penza, S; Porcu, P; Vaughn, J; Williams, N, 2015) |
| "The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL)." | 9.12 | Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). ( Chiao, JH; Duvic, M; Frankel, SR; Hazarika, P; Kelly, C; Ni, X; Reilly, JF; Richon, VM; Ricker, JL; Talpur, R; Zhang, C, 2007) |
| "Hydroxychloroquine (HCQ) enhances the anti-cancer activity of the histone deacetylase inhibitor, vorinostat (VOR), in pre-clinical models and early phase clinical studies of metastatic colorectal cancer (mCRC)." | 7.83 | Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. ( Curiel, T; Goros, M; Hurez, V; Mahalingam, D; Michalek, J; Nawrocki, ST; Patel, S; Sarantopoulos, J, 2016) |
| "Only a minority of patients with high risk lymphoma will be cured with autologous transplant, so maintenance with vorinostat, an oral agent with activity in relapsed lymphoma, was studied starting day + 60 for 21 consecutive days followed by a week off for up to 11 cycles." | 5.20 | A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma. ( Andritsos, LA; Baiocchi, RA; Benson, DM; Bingman, A; Blum, K; Bowers, MA; Devine, SM; Earl, CT; Flynn, J; Geyer, S; Hade, EM; Hofmeister, CC; Humphries, K; Jaglowski, SM; Lozanski, G; Penza, S; Porcu, P; Vaughn, J; Williams, N, 2015) |
| "The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL)." | 5.12 | Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). ( Chiao, JH; Duvic, M; Frankel, SR; Hazarika, P; Kelly, C; Ni, X; Reilly, JF; Richon, VM; Ricker, JL; Talpur, R; Zhang, C, 2007) |
| "Hydroxychloroquine (HCQ) enhances the anti-cancer activity of the histone deacetylase inhibitor, vorinostat (VOR), in pre-clinical models and early phase clinical studies of metastatic colorectal cancer (mCRC)." | 3.83 | Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. ( Curiel, T; Goros, M; Hurez, V; Mahalingam, D; Michalek, J; Nawrocki, ST; Patel, S; Sarantopoulos, J, 2016) |
| "Vorinostat dose levels were 200, 300, and 400 mg orally once daily for 14 days." | 2.84 | Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial. ( Adler, JR; Chang, SD; Choi, CYH; Harsh, GR; Modlin, LA; Neal, JW; Pinder-Schenck, MC; Soltys, SG; Wakelee, HA; Yu, HM, 2017) |
| "Vorinostat-XP is a feasible first-line chemotherapy for patients with advanced GC." | 2.82 | Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis. ( Kang, YK; Lee, CW; Na, YS; Ryoo, BY; Ryu, MH; Yoo, C, 2016) |
| " One week later, daily vorinostat dosing was begun and continued until toxicity or disease progression occurred." | 2.75 | Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. ( Belani, CP; Beumer, JH; Egorin, MJ; Harvey, RD; Holleran, J; Ivy, SP; Kummar, S; Lin, Y; LoRusso, P; Ramalingam, SS; Sarantopoulos, J; Shibata, S; Yerk, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, CYH | 1 |
| Wakelee, HA | 1 |
| Neal, JW | 1 |
| Pinder-Schenck, MC | 1 |
| Yu, HM | 1 |
| Chang, SD | 1 |
| Adler, JR | 1 |
| Modlin, LA | 1 |
| Harsh, GR | 1 |
| Soltys, SG | 1 |
| Andersen, CL | 1 |
| McMullin, MF | 1 |
| Ejerblad, E | 1 |
| Zweegman, S | 1 |
| Harrison, C | 1 |
| Fernandes, S | 1 |
| Bareford, D | 1 |
| Knapper, S | 1 |
| Samuelsson, J | 1 |
| Löfvenberg, E | 1 |
| Linder, O | 1 |
| Andreasson, B | 1 |
| Ahlstrand, E | 1 |
| Jensen, MK | 1 |
| Bjerrum, OW | 1 |
| Vestergaard, H | 1 |
| Larsen, H | 1 |
| Klausen, TW | 1 |
| Mourits-Andersen, T | 1 |
| Hasselbalch, HC | 1 |
| Hofmeister, CC | 1 |
| Williams, N | 1 |
| Geyer, S | 1 |
| Hade, EM | 1 |
| Bowers, MA | 1 |
| Earl, CT | 1 |
| Vaughn, J | 1 |
| Bingman, A | 1 |
| Humphries, K | 1 |
| Lozanski, G | 1 |
| Baiocchi, RA | 1 |
| Jaglowski, SM | 1 |
| Blum, K | 1 |
| Porcu, P | 1 |
| Flynn, J | 1 |
| Penza, S | 1 |
| Benson, DM | 1 |
| Andritsos, LA | 1 |
| Devine, SM | 1 |
| Yoo, C | 1 |
| Ryu, MH | 1 |
| Na, YS | 1 |
| Ryoo, BY | 1 |
| Lee, CW | 1 |
| Kang, YK | 1 |
| Patel, S | 1 |
| Hurez, V | 1 |
| Nawrocki, ST | 1 |
| Goros, M | 1 |
| Michalek, J | 1 |
| Sarantopoulos, J | 2 |
| Curiel, T | 1 |
| Mahalingam, D | 1 |
| Heymann, WR | 1 |
| Ramalingam, SS | 1 |
| Kummar, S | 1 |
| Shibata, S | 1 |
| LoRusso, P | 1 |
| Yerk, M | 1 |
| Holleran, J | 1 |
| Lin, Y | 1 |
| Beumer, JH | 1 |
| Harvey, RD | 1 |
| Ivy, SP | 1 |
| Belani, CP | 1 |
| Egorin, MJ | 1 |
| Duvic, M | 1 |
| Talpur, R | 1 |
| Ni, X | 1 |
| Zhang, C | 1 |
| Hazarika, P | 1 |
| Kelly, C | 1 |
| Chiao, JH | 1 |
| Reilly, JF | 1 |
| Ricker, JL | 1 |
| Richon, VM | 1 |
| Frankel, SR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Histone Deacetylase (HDAC) Inhibition Using Vorinostat (SAHA) After Autologous Hematopoietic Stem Cell Transplantation for High Risk Lymphoma[NCT00561418] | Phase 1 | 23 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Median follow up of living patients (NCT00561418)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| Vorinostat (SAHA) | 23.2 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00561418)
Timeframe: Up to 3 years
| Intervention | patients (Number) | |||
|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease(SD) | Not evaluable | |
| Vorinostat (SAHA) | 13 | 3 | 2 | 5 |
NCI CTCAE version 3.0 was used to assess Adverse Events (AE) Grade 1=Mild AE Grade 2=Moderate AE Grade 3=Severe AE Grade 4=Life-threatening or disabling AE (NCT00561418)
Timeframe: Up to 3 years
| Intervention | patients (Number) | ||||
|---|---|---|---|---|---|
| Fatigue (Grade 1, 2) | Lymphopenia (Grade 1-4) | Thrombocytopenia (Grade 1-3) | Leukopenia (Grade 1-3) | Anemia (Grade 1-3) | |
| Vorinostat (SAHA) | 12 | 11 | 11 | 10 | 10 |
1 review available for vorinostat and Lassitude
| Article | Year |
|---|---|
Treatment of cutaneous T-cell lymphoma: focus on vorinostat.
Topics: Antineoplastic Agents; Fatigue; Gastrointestinal Diseases; Histone Deacetylase Inhibitors; Humans; H | 2008 |
6 trials available for vorinostat and Lassitude
| Article | Year |
|---|---|
Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administratio | 2017 |
A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Fatigue; Female; Gastrointestinal Diseases; Hematologic | 2013 |
A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.
Topics: Administration, Oral; Adult; Aged; Child; Combined Modality Therapy; Diarrhea; Disease-Free Survival | 2015 |
Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis.
Topics: Acetylation; Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Topics: Anorexia; Antineoplastic Agents; Area Under Curve; Diarrhea; Dose-Response Relationship, Drug; Fatig | 2010 |
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dehydration; Disease Progression; Disease-Fre | 2007 |
1 other study available for vorinostat and Lassitude
| Article | Year |
|---|---|
Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Color | 2016 |